KALC 2023

Korean Association for Lung Cancer International Conference

 Lung Cancer, from Challenge to Change

November 30 - December 1, 2023
Lotte Hotel World, Seoul, Korea


Abstract Submission Deadline
October 1, 2023
(24:00 GMT+09:00 Seoul/Japan Time)

Abstract Submission

Abstract Submission Process

  • STEP 1

    Sign UpIf you are already signed-up on this website, you can use the account for your abstract submission.

  • STEP 2

    Submission and ConfirmationAfter your abstract submission, a confirmation letter will be sent to you via e-mail.

  • STEP 3

    My PageTo review or modify your submitted abstracts, visit 'My Page'.

  • STEP 4

    Acceptance NotificationAn acceptance notification will be sent to you via e-mail.

Important Notes:

  • The Presenting Author of the abstract must be one of the authors listed in the abstract.
  • The submitter should be the first author of the paper.
  • The Presenting Author must register for the conference.
  • Abstracts must be submitted in English.

Abstract Category

An abstract can be submitted for presentation at the conference in one of the following categories:

  • Oral Presentation
  • OR
  • Poster Presentation

Guidelines for Abstract Submission

Please adhere to the following formatting guidelines when submitting abstracts for the conference. 

  • The Title should not exceed 20 words (First letter of each word in uppercase, except for articles, prepositions, and conjunctions).
  • Name and Affiliation of Presenting Author (this person will act as the main contact for this abstract)
  • Name and Affiliation of Co-author(s) and confirmation that all authors have consented to the submission. 
  • The Abstract Text should not exceed 300 words (excluding the Title, Authors, and Affiliations).
  • An Acceptable Structure of an abstract must consist of the following components:
  • Background/Aim: A statement of the hypothesis or research question.
  • Methods: An explanation of the study design and experimental methods used.
  • Results:
    • A concise summary of the major findings of the experiment or study.
    • Sufficient data must be provided to permit evaluation by the reviewers and public reading the abstract.
    • Statements such as “The data will be discussed“ are not acceptable.
  • Conclusion(s): Summary of the overall findings and the importance of the study.
  • Graphics and Tables can be submitted as part of an abstract. The maximum file size of each graphic/tables is 500 KB.

Suggested Topics for Abstract Submission are:

  • Category I
  • Basic & Translational Research / Biology / Pathology
  • Pulmonology / Endoscopy
  • Radiology / Staging / Screening / Epidemiology
  • Big Data & AI
  • Others
  • Category II
  • Early / Locally Advanced Non-Small Cell Lung Cancer
  • Surgery
  • Radiotherapy
  • Mesothelioma / Thymic & Other Thoracic Malignancies
  • Category III
  • Advanced Non-Small Cell Lung Cancer / Chemotherapy / Targeted Therapy / Immunotherapy
  • Small Cell Lung Cancer / Neuroendocrine Tumors
  • Palliative Care

Notification of Acceptance

  • Presenting Authors will be notified of their acceptance status via email. Presenting Authors must inform any co-author(s) of acceptance.
  • The Organizing Committee reserves the right to accept or decline any submissions and to select the presentation format.

Abstract Modification or Withdrawal

  • Presenting Authors may modify or withdraw the submitted abstract by the submission deadline.


  • For questions regarding Abstract Submission, please contact us via email kalcic@hbni.co.kr.